President Trump on Friday quietly signed into law a sweeping measure that will help ensure the Food and Drug Administration can continue to oversee drug and device approvals.

It’s a victory for the pharmaceutical industry, which, together with the FDA, fought to ensure the package would become law before existing agreements expire at the end of September. The industry will pay more than $1 billion toward the agency’s oversight efforts, per an agreement hammered out with lawmakers and the FDA. Both industry and the agency say the so-called user fees are critical to keeping the lights on at the FDA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • So. Does this mean user fee biggest fee paid gets industries product pushed forward faster into commercial production?product

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy